Development of New Oral Drug for Treating Chronic Mercury Exposure | Wassana Yantasee, PhD, MBA

Development of New Oral Drug for Treating Chronic Mercury Exposure | Wassana Yantasee, PhD, MBA

IAOMT Annual Conference in Stowe, VT
September 8, 2018

Learning Objectives:
1. Discuss how the oral drug for chelating mercury was developed and screened
from various candidates.
2. Review how the lead material (SH-SAMMS) has desirable characteristics for GI
tract capture of mercury.
3.  Discuss how SH-SAMMS prevents accessibility of gut bacteria to mercury,
hence preventing bacterial conversion of mercury to a more absorbable form and
limiting mercury toxicity to gut bacteria.

Dr. Wassana Yantasee is an Associate Professor in the Biomedical Engineering Department at Oregon Health and Science University School of Medicine and the President/CEO of PDX Pharmaceuticals, LLC. She received a PhD in Chemical Engineering and MBA from Oregon State University in 2001. Her research interest is on the development of nanomaterials for the capture and sensing of toxic metals, as well as for siRNA and drug delivery to treat cancer and fibrosis, and this has resulted in 60 journal articles and 7 book chapters. She was inducted into the OSU’s Council of Outstanding Early Career Engineers in 2014 and has served as a reviewer for 27 Scientific Review panels for the National Institute of Health.

Disclaimer: The information provided on this video is not intended as medical advice and should not be interpreted as such. If you seek medical advice, please consult with a health care professional. Also, the information in this video represents the thoughts of the individual speaker/s, and the views expressed in this interview do not necessarily reflect the views of the IAOMT, its individual members, its Executive Committee, its Scientific Advisory Council, its administration, its employees, contractors, sponsors, or any other IAOMT affiliates.